135091662 Age 45 Years Gender Male 29/8/2017 120000AM 29/8/2017 100215AM 29/8/2017 110825AM Ref By Final RHEUMATOID AUTOIMMUNE COMREHENSIVE ANEL ANTI NUCLEAR ANTIBODY / FACTOR (ANA/ANF), SERUM ----- 20-60 Moderate positive >60 Strong positive ----- 5.00 Units <20.00 Antinuclear antibodies are the most sensitive screening test for autoantibodies in patients suspected of connective tissue diseases. They are a heterogenous group of autoantibodies directed against ds-dna, histones, SSA / Ro, SSB / La, Sm, Sm / RN, Scl-70, Jo-1 & Centromere. ANA s have also been detected in patients with Autoimmune Hepatitis (80%),rimary biliary cirrhosis (60%), Alcohol related liver disease (50%), Viral hepatitis B (40%). resence of ANA has also been detected in individuals taking certain drugs like Hydrallazine, Isoniazid, Chlorpromazine; family of SLE patients; healthy and elderly persons ANTI - ds DNA ANTIBODY, SERUM -- RESULT IN IU/mL REMARKS <30 Negative 30-75 Equivocal >75 ositive -- 12.00 IU/mL <30.00 Anti double stranded DNA (ds DNA) antibodies are specific for SLE observed in 40-90% of these patients with active disease. American Rheumatoid arthritis association considers the presence of ds-dna antibody as a diagnostic criteria for SLE. These antibodies are directly involved in the disease process being deposited as DNA / Anti DNA immune complexes. This test is used for diagnosis and monitoring of SLE with atientreportscsuperanel.s_general_temlate01_sc (Version 7) age 1 of 5
135091662 Age 45 Years Gender Male 29/8/2017 120000AM 29/8/2017 100215AM 29/8/2017 110825AM Ref By Final high levels being associated with exacerbation of disease activity and lower levels correlating with remission. They may be raised in patients with Discoid lupus erythematosus. All SLE patients may not show elevated ds-dna antibodies especially those at the peak of SLE exacerbation. In some cases the level may remain elevated even during the remission phase of the disease. C3 COMLEMENT, SERUM 139.00 mg/dl 90.00-180.00 Complement C3 is required for the activation of all three pathways namely classic pathway, properdin pathway and MB pathway. C3 deficiency may result in neumococcal and Neisserial infections as well as autoimmune diseases like Glomerulonephritis. It also acts as an acute phase reactant and levels rise after trauma, surgery and during inflammatory processes. Increased Levels - Acute phase response, Biliary obstruction & Focal glomerulosclerosis Decreased Levels - Infancy, Genetic deficiency, Acquired deficiency like Lupus nephritis, Collagen vascular diseases & severe infections C4 COMLEMENT, SERUM 22.00 mg/dl 10.00-40.00 Complement C4 deficiency results in the inability of Immune complexes to activate the complement pathway. This results in inability to generate peptides that clear the immune complexes or generate lytic activity. Hence these patients have increased susceptibility to infections especially with encapsulated microorganisms. C4 deficiency may be an etiologic factor in the development of autoimmune disease.. Increased Levels - Acute phase reaction due to inflammation, trauma & tissue necrosis. Decreased Levels - Infancy, Genetic deficiency & Acquired deficiency as in SLE, Angioedema, Autoimmune hemolytic anemia and Autoimmune nephritis. CENTROMERE ANTIBODY, SERUM 4.00 Units <20.00 atientreportscsuperanel.s_general_temlate01_sc (Version 7) age 2 of 5
135091662 Age 45 Years Gender Male 29/8/2017 120000AM 29/8/2017 100215AM 29/8/2017 110825AM Ref By Final 20-30 Weak ositive >30 Strong ositive Centromere antibodies are associated with Scleroderma, a multisystem connective tissue disorder with vascular lesions and tissue fibrosis. atients with Systemic Sclerosis spontaneously produce autoantibodies against nuclear, nucleolar and mitochondrial antigens which are of diagnostic and prognostic significance. Autoantibodies to centromere proteins are present in 50-80% CREST subset; 25% patients with idiopathic Raynaud s phenomenon and 8% with diffuse form of the disease. Centromere antibodies are most often associated with lower frequency of pulmonary fibrosis and mortality although an increased risk for pulmonary hypertension has been observed. RHEUMATOID FACTOR (RA), SERUM 12.00 IU/mL <14.00 Rheumatoid factor is an antibody directed against the Fc portion of the IgG molecule. olyreactive RF has binding specificity for substances other than IgG like nuclear components. This polyreactive RF is usually of the IgM class with low affinity. RF is not specific only for Rheumatoid arthritis, but it is often seen in cases of chronic infection and other systemic inflammatory conditions. Healthy individuals > 65 years of age may also show positive RF results. In addition to the common IgM RF, both IgA RF & IgG RF have been detected. IgA RF has been related to the more severe form of the disease with erosions. Sm (SMITH), ANTIBODY, IgG, SERUM 20-39 Weak ositive 40-80 Moderate ositive >80 Strong ositive 12.00 Units <20.00 Antibodies to Smith antigen are considered a highly specific marker for SLE. They usually occur in association with nuclear Ribonuclear proteins (nrn). SLE patients with presence of Anti Sm antibodies usually have associated renal disease and / or disorders of central nervous system. atientreportscsuperanel.s_general_temlate01_sc (Version 7) age 3 of 5
135091662 Age 45 Years Gender Male 29/8/2017 120000AM 29/8/2017 100215AM 29/8/2017 110825AM Ref By Final SSA/Ro ANTIBODY, SERUM 20-39 Weak ositive 40-80 Moderate ositive >80 Strong ositive 3.00 Units <20.00 atients with SLE may have antibodies to SSA/Ro alone or may have both SSA/Ro & SSB/La antibodies. resence of SSA/Ro antibody alone is commonly seen in association with HLA DR2 in patients less than 22 years of age at onset. resence of both SSA/Ro & SSB/La in SLE is associated with HLA DR3 and is seen in older patients more than 50 years of age at onset. SLE patients with SSA/Ro antibodies develop a much more serious renal disease and have a higher incidence of concomitant Anti DNA antibodies. Increased levels Subacute cutaneous Lupus erythematosus Neonatal Lupus erythematosus syndrome with congenital heart block and cutaneous lesions Homozygous C2 & C4 deficiency with SLE like disease rimary Sjogren s syndrome vasculitis, Rheumatoid factor positivity & severe systemic symptoms ANA negative SLE patients SLE with Interstitial pneumonitis SSB/La ANTIBODY, SERUM 20-39 Weak ositive 40-80 Moderate ositive atientreportscsuperanel.s_general_temlate01_sc (Version 7) 4.00 Units <20.00 age 4 of 5
135091662 Age 45 Years Gender Male 29/8/2017 120000AM 29/8/2017 100215AM 29/8/2017 110825AM Ref By Final >80 Strong ositive SSB/La antibodies are primarily considered as a serological marker of rimary Sjogren s syndrome and are detected in nearly 90% of these patients. They are also seen in 6-15% cases of ANA positive SLE patients. resence of both SSB / La & SSA/Ro antibodies in SLE patients shows a lower incidence of renal disease and lower levels of concomitant Anti DNA antibodies. Detection of this antibody can precede the development of symptoms of Sicca syndrome by several years. U1RN ANTIBODIES, SERUM - RESULT IN Units REMARKS 20-39 Weak ositive 40-80 Moderately ositive --------------- ------------------------ >80 Strong ositive - 5.00 Units <20.00 Antibodies to both Sm (Smith) & nuclear ribonuclear proteins(nrn) are found in patients with SLE. When Anti RN antibodies are found in higher titers in patients sera, usually in the absence of Anti smith antibodies, they are associated with Mixed Connective Tissue Disease (MCTD). SLE patients who have antibodies to only nrn have a lower frequency of DNA antibodies and lower incidence of clinically apparent renal disease. Dr. Ritu Nayar MD (Microbiology) Deputy HOD Microbiology & Serology Dr. Shalabh Malik MD (Microbiology) National Head - Microbiology & Serology Dr Himangshu Mazumdar MD (Biochemistry) Consultant Biochemist -------------------------------End of report -------------------------------- Dr. Nimmi Kansal MD (Biochemistry) HOD Biochem & IA atientreportscsuperanel.s_general_temlate01_sc (Version 7) age 5 of 5